The U.S. Food and Drug Administration has given Medtronic (NYSE:MDT) the go-ahead on a clinical trial to test its next generation of MRI pacemaker technology, the Minnesota company announced Monday.

The U.S. FDA recently granted Medtronic plc approval for its deep brain stimulation (DBS) system to be used to treat Parkinson’s disease or essential tremor while a patient is asleep, under general ...

Medical device company Medtronic has introduced in Europe a line of spinal cord stimulators for chronic back and leg pain that are compatible with magnetic resonance imaging, according to American ...

DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation approach to ...